Notis McConarty Edward Buys Shares of 3,106 Stryker Corporation $SYK

Notis McConarty Edward bought a new position in Stryker Corporation (NYSE:SYK) in the second quarter, HoldingsChannel reports. The institutional investor bought 3,106 shares of the medical technology company’s stock, valued at approximately $978,000.

Other hedge funds have also recently modified their holdings of the company. Gables Capital Management Inc. purchased a new stake in shares of Stryker during the second quarter valued at $25,000. Godfrey Financial Associates Inc. bought a new stake in Stryker in the 4th quarter worth about $26,000. Sankala Group LLC purchased a new position in Stryker in the 4th quarter worth about $26,000. United Financial Planning Group LLC bought a new position in Stryker during the 3rd quarter valued at about $27,000. Finally, Atlas Capital Advisors Inc. bought a new position in Stryker during the 4th quarter valued at about $27,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity

In related news, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 315,370 shares of company stock worth $98,463,501 over the last quarter. Insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Royal Bank Of Canada reduced their price target on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. UBS Group assumed coverage on shares of Stryker in a research report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price objective on the stock. Needham & Company LLC dropped their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Raymond James Financial set a $370.00 target price on shares of Stryker in a research report on Friday, July 31st. Finally, Evercore set a $350.00 target price on shares of Stryker in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Stock Up 2.7%

SYK stock opened at $340.20 on Thursday. The business’s 50-day moving average price is $326.19 and its 200-day moving average price is $332.95. The stock has a market cap of $130.49 billion, a P/E ratio of 35.25, a PEG ratio of 2.11 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the prior year, the company posted $3.13 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.